Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics Plans $3.6M Public Stock Offering

NEW YORK (GenomeWeb) – Interpace Diagnostics Group announced today that it is planning a $3.6 million public offering of common stock.

The company is offering 1.2 million shares of stock at a public offering price of $3 per share. It expects to receive gross proceeds of approximately $3.6 million, before deducting underwriting discounts and commissions, and other estimated offering expenses. Interpace has also granted the underwriters an over-allotment option to purchase up to an additional 108,000 shares. The offering is expected to close on or about Feb. 8.

Interpace said it intends to use the net proceeds for working capital, to repay debt and other liabilities, and for general corporate purposes.

Maxim Group is acting as sole book-running manager for the offering. Roth Capital Partners is serving as financial advisor.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.